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Why We Will Never Stop Aspirating Coronary Thrombi*James C. Blankenship, MD, MHCMSEE PAGE 113I n 1988 Topol coined the term “oculostenoticreﬂex” to describe the “irresistible temptationamong some invasive cardiologists to perform
angioplasty on any signiﬁcant residual stenosis after
thrombolysis” (1). Similarly, many operators ﬁnd the
temptation to aspirate thrombi irresistible, particu-
larly when they sometimes extract magniﬁcent red
thrombi approaching the size of nightcrawlers
(Figure 1). We propose that this phenomena be termed
the “oculothrombotic reﬂex.” Although the oculoste-
notic reﬂex has been widely condemned (2), the
appropriateness of the oculothrombotic reﬂex is
under debate. Recent reports have not been encour-
aging for aspiring aspirators.
THE STATE OF CORONARY THROMBUS
ASPIRATION
Coronary thrombus aspiration (CTA) has been exten-
sively tested in ST-elevation myocardial infarction
(STEMI) patients undergoing primary percutaneous
coronary intervention (PPCI). Early reports were
favorable. CTA was associated with decreased mor-
tality in randomized trials (3,4) and meta-analyses
(5,6). However, more recent, larger trials (7,8) and
meta-analyses (9,10) have found no improvement in
clinical endpoints with CTA. As a consequence, an
American College of Cardiology (ACC)/American
Heart Association (AHA)/Society for Cardiac Angiog-
raphy and Interventions (SCAI) guideline update
published online in October 2015 downgraded routine
CTA in STEMI from a IIa recommendation to a class III
recommendation.*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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TOTAL trial.These negative ﬁndings are mirrored in large reg-
istries comparing nonrandomized use of CTA versus
no CTA in PPCI in over 27,000 patients. Nor has CTA
fared better in other acute coronary syndromes. The
TATORT (Thrombus Aspiration in Thrombus Con-
taining Culprit Lesions in Non–ST-Elevation Myocar-
dial Infarction trial) found no beneﬁt from CTA in
percutaneous coronary intervention (PCI) for non-
STEMI (11).
DELAYED CTA AND PCI IN STEMI
Current STEMI guidelines rate PPCI in the ﬁrst 12 h as
a class I recommendation, and PPCI 12 to 24 h after
symptom onset with ongoing signs or symptoms of
ischemia as a class IIa recommendation. The ACC/
AHA/SCAI guidelines do not discuss PPCI after 24 h,
but the most recent European Society of Cardiology
guidelines upgraded PPCI at 12 to 48 h after symptom
onset in STEMI to a IIb recommendation.With this background, in this issue of JACC
Cardiovascular Intervention, Desch et al. (12) present
the results of a randomized study of 152 STEMI pa-
tients presenting 12 to 48 h after the onset of symp-
toms who were randomized to CTA versus no CTA
before PPCI. The primary endpoint was extent of
microvascular obstruction as measured by cardiac
magnetic resonance imaging. The secondary end-
points were surrogates of myocardial perfusion,
including infarct size, myocardial salvage, left ven-
tricular volumes, ejection fraction, myocardial blush
grade, ﬁnal thrombolysis in myocardial infarction
ﬂow, and clinical endpoints (for which the study was
underpowered).
The investigators hypothesized that CTA might be
more effective in delayed PPCI than in PPCI for STEMI
at <12 h after the onset of symptoms. Older thrombi
FIGURE 1 Coronary Thrombus Aspiration
(A) Coronary thrombus aspirated during primary percutaneous coronary intervention in a patient with ST-segment elevation myocardial
infarction. The thrombus could not be fully aspirated into the catheter and was removed with suction applied to the catheter. The distal end of
the thrombus is seen protruding from the aspiration lumen of the catheter. (B) The thrombus, more than 3 cm long, rests on a ruler.
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124are more consolidated and might be more likely to
embolize downstream if mechanically impacted by an
angioplasty balloon (13), thus obstructing collateral
ﬂow and causing additional infarction. The CTA of
such thrombi might avoid downstream embolization.
This might explain why, in the VAMPIRE (VAcuuM
asPIration thrombus Removal) trial, which enrolled
patients up to 24 h after the onset of symptoms, CTA
had a more beneﬁcial effect on markers of myocardial
reperfusion in late presenters (>6 h) compared with
early presenters (<6 h) (14).
Contrary to their hypothesis, for the primary
endpoint and all secondary endpoints Desch et al. (12)
found no signiﬁcant differences between CTA and no
CTA before PPCI.
In general, the study was well designed and well
conducted. It was adequately powered for its pri-
mary endpoint. Cardiac resonance images were
analyzed in an experienced core laboratory. Cross-
over between groups was low. The success rate of
CTA in crossing the culprit lesions was 93%, better
than reported in most other trials of CTA. It did have
several weaknesses, including the following: 1) it was
performed at a single center; 2) the interventionists
were not blinded to the study assignments (although
the patients and all other study personnel were
blinded); 3) possibly too little viable myocardium
remains after 12–48 h for any interventional strategy
to show a beneﬁt; and 4) the primary endpoint
was a marker of reperfusion, a surrogate for
clinical endpoints. (The clinical signiﬁcance of sur-
rogates is uncertain because several studies have
demonstrated that CTA with PPCI improves surro-
gate outcomes without improving clinical outcomes
[3,10,14–17].)WILL THESE NEGATIVE RESULTS KILL CTA?
Recent editorialists, commenting on studies showing
no clinical beneﬁt of CTA, have opined that operators
will continue to perform CTA. Why? Several reasons
come to mind.
1. The oculothrombotic reﬂex. When operators see a
large thrombus, the ease and intuitive appeal of
CTA will continue to make it an attractive option.
2. CTA makes PPCI in STEMI easier. It allows more
frequent direct stenting, which itself may decrease
infarct size (18). Additionally, CTA may reduce
distal embolization (14), saving operators the dif-
ﬁculty of chasing thrombi that embolize down-
stream and occlude the distal artery.
3. Studies provide evidence that routine CTA is not
helpful, but selective CTA may be beneﬁcial.
Selective CTA with PPCI is a IIb recommendation in
the ACC/AHA/SCAI STEMI guidelines published
online in October 2015. Proponents of this view will
cite 2 studies of patients with obvious thrombus
randomized between CTA and no CTA before PPCI.
One study found an improved myocardial salvage
index and reduced infarct size in the CTA arm (14).
The second study demonstrated that CTA improved
the myocardial blush grade and microvascular
obstruction (but not infarct size) (19). (Both studies
were underpowered for clinical endpoints.)
4. Many randomized studies showed no difference in
clinical outcomes with CTA (7,8,14,19), but others
have suggested that CTA did improve clinical out-
comes (3,15,20,21). Do interventionists in the
Netherlands know how to perform CTA better than
interventionists elsewhere, such that the large
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125TAPAS (Thrombus Aspiration during Percutaneous
coronary intervention in Acute myocardial infarc-
tion Study) (3) showed a beneﬁt for CTA? Most of
these trials did not specify the CTA techniques,
and operators may have developed individual
tricks or techniques that are more successful than
those used in the large trials.
SUMMARY
Routine CTA with PPCI appears to be discredited, and
there is little hard evidence to support even selective
CTA. However, interventionists are likely to continue
to use CTA because of the oculothrombotic reﬂex, the
visual gratiﬁcation of occasionally extracting large
thrombi from coronary arteries, and the sense thatCTA makes STEMI PCI easier when a large thrombus
burden is present. New technologies such as novel
thrombus retrieval devices or the MGuard mesh stent
(InspireMD, Boston, Massachusetts) may replace CTA
in the future, but for now it seems clear that in-
terventionists will retain CTA catheters in their
toolkits.
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